Results 301 to 310 of about 521,269 (357)

ESCRT‐Mimetic Nanodegrader Targets STING for Anti‐Inflammatory Therapy

Advanced Science, EarlyView.
A nanoplatform‐enabled targeted protein degradation strategy is presented to regulate aberrant STING signaling. STING‐ATTEC induces selective autophagic degradation of STING via formation of a STING–ATTEC–LC3 ternary complex, while the cationic FA‐LNP+ system enhances LC3 generation and targeted delivery. Together, this synergistic approach efficiently
Fuyuan Zhou, Qiming Zhai, Zhihao Yao, Qing Li, Yan Yang, Si Wang, Chao Huang, Liangjing Xin, Tao Chen, Jinlin Song   +9 more
wiley   +1 more source

Epigenetic lockdown of type I interferon sensing and signalling in human pluripotent cells

Holt JH, Enriquez-Gasca R, Wilson RP, Bochukova EG, Maillard PV, Rowe HM.   +5 more
europepmc   +1 more source

RACK1 Associates With STING to Promote Type I Interferon Activation and Inhibit Pseudorabies Virus Infection. [PDF]

Transbound Emerg Dis
Li Y, Liu Y, Dai Y, Niu J, Li G, Yu X, Wan C, Fang R, Ye C.   +8 more
europepmc   +1 more source

Immune horses rapidly increase antileukoproteinase and lack type I interferon secretion during mucosal innate immune responses against equine herpesvirus type 1

Camille M. Holmes, Susanna Babasyan, Naya A. Eady, Christiane L. Schnabel, Bettina Wagner   +4 more
openalex   +1 more source

Albumin‐Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8+ T Cell Immunity

Advanced Science, EarlyView.
This study demonstrates that an albumin‐bound STING agonist (Nano ZSA‐51D) reprograms HSPCs to produce antitumor neutrophils with enhanced MHC I–mediated CD8+ T cell activation, thereby sensitizing tumors to α‐PD1 therapy. These findings highlight a strategy to target early hematopoiesis for shaping neutrophil fate and potentiating cancer immunotherapy.
Jinsong Tao, Hong‐Yi Zhao, Chengyi Li, Hanning Wen, Fang Ke, Qiuxia Li, Miao He, Bo Wen, Zhongwei Liu, Kai Sun, Wei Gao, Duxin Sun   +11 more
wiley   +1 more source

Type I interferon restricts mRNA vaccine efficacy through suppression of antigen uptake in cDCs. [PDF]

NPJ Vaccines
Lobb TA, Dickson A, Guo W, Beeram S, Carrero JA, Dalben Y, DiPaolo RJ, Alspach E, Tse LV, Ferris ST.   +9 more
europepmc   +1 more source

TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer. [PDF]

Oncogene
Wu WY, Yang YS, Andriani L, Xie YF, Di GH, Shao ZM, Li JJ.   +6 more
europepmc   +1 more source

The Type I Interferon Axis in Systemic Autoimmune Diseases: From Molecular Pathways to Targeted Therapy. [PDF]

Biomolecules
Ishihara R, Watanabe R, Shiomi M, Fujita Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M.   +7 more
europepmc   +1 more source

Duck lncRNA lnc455 enhances RIG-I/MAVS type I interferon signaling by modulating hnRNPAB-mediated regulation of MAVS signaling. [PDF]

Sci Rep
Legaspi RJ, Magor KE.
europepmc   +1 more source

BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity. [PDF]

Nat Commun
Gong W, Taner HF, Wu Y, He Y, Zhou X, Li Z, Hu X, Ursin C, Debnath KC, Okuyama K, Hu Q, Donnelly CR, Nör F, Perera CD, Bellile E, Yunesi A, Zhai Z, Zhao M, Cheng W, Fitzsimonds ZR, Broses L, Li J, Demehri S, Nagrath D, Wolf GT, Sikora AG, Yu Y, Wen H, Wei L, Chinn SB, Myers JN, Akira S, Xie Y, Moon JJ, Lei YL.   +34 more
europepmc   +1 more source